Company Encyclopedia
View More
name
Kazia Therapeutics
KZIA.US
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute.
1.946 T
KZIA.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking308/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE226.03%A
    • Profit Margin-1131.88%E
    • Gross Margin100.00%A
  • Growth ScoreD
    • Revenue YoY-27.83%E
    • Net Profit YoY24.32%B
    • Total Assets YoY-72.53%E
    • Net Assets YoY18.94%A
  • Cash ScoreD
    • Cash Flow Margin-8.83%D
    • OCF YoY-27.83%E
  • Operating ScoreE
    • Turnover0.13E
  • Debt ScoreE
    • Gearing Ratio236.96%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities | KZIA Stock News

    Kazia Therapeutics announced a $50 million private placement of equity securities with institutional investors, led by healthcare-focused firms. The proceeds will support clinical development of its lead program, paxalisib, and extend its cash runway into 2028. The transaction is expected to close on December 3, 2025, subject to conditions. The securities are not registered under the Securities Act and will require a shelf registration statement for resale.

    StockTitan·
    US
    KZIA
    +0.98%
    StockTitan·
    US
    KZIA
    +0.98%

    BUZZ-Microcap Kazia shares soar 40% after positive drug update on single-patient treatment

    Shares of Kazia Therapeutics surged 34% to $7.79 after reporting positive early-stage results in a patient with stage IV triple-negative breast cancer using a combination of Kazia's drug, paxalisib, and Merck's Keytruda. The treatment achieved an initial immune-complete response. Kazia has 1.67 million shares outstanding and a market value of $9.6 million. The session high was $8.54, the highest since September 11. Merck shares remained unchanged at $96.52.

    Reuters·
    US
    MRK
    -1.35%
    US
    KZIA
    +0.98%
    Reuters·
    US
    MRK
    -1.35%
    US
    KZIA
    +0.98%

    Promising Developments in Oncology Drive Buy Rating for Kazia Therapeutics

    Promising Developments in Oncology Drive Buy Rating for Kazia Therapeutics

    Tip Ranks·
    US
    KZIA
    +0.98%
    Tip Ranks·
    US
    KZIA
    +0.98%

    Kazia Therapeutics shares are trading higher after the company reported an initial immune-complete response in a stage IV triple-negative breast cancer patient treated under an FDA-authorized expanded access protocol combining paxalisib with pembrolizumab and chemotherapy.

    benzinga_article·
    US
    KZIA
    +0.98%
    benzinga_article·
    US
    KZIA
    +0.98%

    Kazia Therapeutics Reports Initial iCR in Metastatic TNBC and Advances Pipeline Programs

    Kazia Therapeutics announced an initial immune-complete response in a stage IV triple-negative breast cancer patient treated with paxalisib, pembrolizumab, and chemotherapy. The company also reported progress in its glioblastoma program and advancements in its NDL2 PD-L1 degrader program. Additionally, Kazia received a Nasdaq non-compliance notice regarding market value requirements, with a deadline to regain compliance by November 10, 2025.

    Reuters·
    US
    KZIA
    +0.98%
    Reuters·
    US
    KZIA
    +0.98%
    © 2025 Longbridge｜Disclaimer